GPLB Green Planet Bio Engineering Co. Ltd.
Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 1392449 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-28.6%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA—
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets—
Debt / equity—
Current ratio0.00x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.32x
Accruals ratio—
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| SG&A expense | $8,440 | $5,905 | $10,794 | $16,298 | $8,599 | $4,105 | $6,840 | $12,791 |
| Interest expense | — | — | $150 | — | — | — | — | — |
| Pretax income | -$8,440 | -$5,905 | -$10,944 | -$16,298 | -$8,599 | -$4,105 | -$6,840 | -$12,791 |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$8,440 | -$5,905 | -$10,944 | -$16,298 | -$8,599 | -$4,105 | -$6,840 | -$12,791 |
| EPS (diluted) | 0.00 | 0.00 | — | — | 0.00 | 0.00 | 0.00 | — |
| Weighted avg. shares (diluted) | 20.01M | 20.01M | 20.01M | — | 20.01M | 20.01M | 20.01M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total assets | — | — | — | — | — | — | — | — |
| Current liabilities | $526,265 | $517,825 | $511,920 | $500,976 | $484,678 | $476,079 | $471,974 | $465,134 |
| Total liabilities | $526,265 | $517,825 | $511,920 | $500,976 | $484,678 | $476,079 | $471,974 | $465,134 |
| Shareholders' equity | -$526,265 | -$517,825 | -$511,920 | -$500,976 | -$484,678 | -$476,079 | -$471,974 | -$465,134 |
| Shares outstanding | 20.01M | 20.01M | 20.01M | 20.01M | 20.01M | 20.01M | 20.01M | 20.01M |
| Cash flow statement | ||||||||
| Operating cash flow | -$8,440 | -$12,654 | -$16,643 | -$17,030 | -$6,569 | -$6,030 | -$6,915 | -$11,291 |
| Investing cash flow | — | $0 | $0 | — | $0 | $0 | $0 | $35,044 |
| Financing cash flow | $8,440 | $12,654 | $16,643 | $17,030 | $6,569 | $6,030 | $6,915 | $11,291 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.